← BeOne Medicines Ltd. (BEIGF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BeOne Medicines Ltd. (BEIGF)
Pharmaceutical Preparations · market cap $32.4B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
17
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
BeOne Medicines Ltd. (BEIGF) is a global biotechnology company with approximately 11,000 employees and a market cap of roughly $40.9 billion. Its pipeline centers on hematologic malignancies, with lead assets sonrotoclax (Phase 3, Waldenstrom Macroglobulinemia), zanubrutinib (Phase 3, Chronic Lymphocytic Leukemia), and BGB-16673 (Phase 2, B-cell malignancies). Two Phase 2 readouts are expected in the second half of 2026, making this a catalyst-rich window.
The catalyst path
- 2026-11-15 (est.)Phase 2 · Dexamethasoneimp 7/10
- 2026-11-15 (est.)Phase 3 · BGB-16673imp 9/10
- 2026-12-31 (est.)Phase 2 · Fludarabineimp 7/10
- 2027-03-31 (est.)Phase 2 · BGB-B2033imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PD-1/PD-L1 inhibitors | Phase 2 | Borderline Resectable Carcinoma |
| ZW25 (Zanidatamab) | Phase 2 | HER2-amplified Biliary Tract Cancers |
| Tacabrutideg | Phase 3 | Chronic Lymphocytic Leukemia |
| BGB-16673 | Phase 3 | B-cell Malignancy |
| Sonrotoclax | Phase 3 | Waldenstrom Macroglobulinemia |
| Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia |
| Tislelizumab | Phase 3 | Colorectal Cancer |
| CAR-T Cell Therapy | Phase 2 | Mantle Cell Lymphoma |
| Blinatumomab | Phase 2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia |
| Fludarabine | Phase 2 | Recurrent Transformed Chronic Lymphocytic Leukemia |
| BGB-11417 | Phase 2 | Acute Myeloid Leukemia |
| bendamustine | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma |
| Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma |
| Tacrolimus | Phase 3 | Primary Membranous Nephropathy |
| Oxaliplatin | Phase 3 | Advanced Unresectable Gastric Adenocarcinoma |
| Leucovorin | Phase 2 | Gastroesophageal Adenocarcinoma |
| BGB-B2033 | Phase 2 | Metastatic Hepatocellular Carcinoma |
Price & technical context
3-month
+0.0%
6-month
-7.6%
12-month
+37.6%
52-wk range
$15.95–$25.29
vs 50-day MA
-0.0%
vs 200-day MA
-5.3%
Realized vol
45.5%
Max drawdown
-22.6%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BEIGF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.